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Abstract
Background:  A number of reports showed en encouraging remediation in some patients'
executive deficits thanks to the use of 'information processing strategies'. Moreover the impact of
antipsychotics on cognitive functions of the schizophrenics is an important issue, especially if an
integrated psychosocial treatment is needed.
The aim of this paper is to evaluate different executive performance and response to verbalization,
a strategy of the Wisconsin Card Sorting Test (WCST) remediation, in subjects on classical vs
atypical antipsychotic (AP) treatment.
Methods: Sixty-three schizophrenic subjects undertook the WCST under standard and modified
(verbalization) administration. Subjects were stratified by the kind of WCST response (i.e. good,
poor and remediable) and AP treatment (i.e. atypical vs. classical).
Results: Subjects on atypical APs showed a better performance than those on classical ones. More
poor performers who did not remediate were seen in the sample with classical Aps while subjects
who remediated the performance were seen in the subgroup with atypical APs only. An increase
of perseverative and total errors was seen in poor performers subjects on classical APs.
Conclusion:  Subjects on atypicals showed a better cognitive pattern in terms of WCST
performance. Since the naturalistic assignment of medication we cannot draw conclusions about its
effect on cognitive performance and its interaction with cognitive remediation potential. However
the data lead us to hypothesize that subjects with potential room for remediation did so with the
atypical APs.
Background
Cognitive deficits are important targets for intervention in
patients with schizophrenia to favor clinical and func-
tional success. Executive skills are relevant for dealing
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with novel and complex situations, crucial for occupa-
tional outcome and independent living of people with
schizophrenia [1,2]. Several studies reported that a large
part of these people improve their executive performance
by remediation strategies and cognitive therapies [3-5].
A number of reports showed en encouraging remediation
in some patients' executive deficits thanks to the use of
'information processing strategies'. This has been mostly
investigated using Wisconsin Card Sorting Test (WCST),
and verbalization has been found the most efficacious
procedure to obtain the performance improvement.
Cumulatively, these data suggest that a simple instruction
may enhance executive function and affect WCST per-
formance in patients with schizophrenia [6-9].
In our previous studies on remediation of WCST perform-
ance of persons with schizophrenia we hypothesised that
the improvement could be attained through a cognitive
strategy that bounds schizophrenic patients to use a con-
ceptually driven processing. Using verbalization as such a
strategy, we observed that when the patients were required
to verbally express the matching criterion before the card
sorting, a remediation of the poor WCST response
occurred [10,11]. Furthermore, we observed different pat-
terns of response to verbalization, i.e. improvement or
worsening of the performance. About the 63% of the
WCST poor performers improved while the remaining
patients, showed an increase of perseverative errors. The
latter subjects were characterized by more negative symp-
toms, poor outcome and earlier age at onset. On the basis
of these observations we hypothesized that this modified
WCST administration could be used as a criterion that, if
validated, could be able to unveil different patient sub-
group with different pathophysiological trajectories.
The impact of antipsychotics (APs) on cognitive functions
of the schizophrenics is an important issue, especially if
an integrated psychosocial treatment is needed [2]. Even
though cognitive enhancement in schizophrenia is far
from being a resolved issue [12], there is evidence that
atypical APs can provide some cognitive benefit (for
reviews see [1,13]]. However, caution is needed before
generalize the results of these studies because the limited
effect size and deficient methodologies [13].
The aim of this study is to compare the cognitive perform-




A sample of 63 consecutive out-patients (18 females and
45 males) who met the DSMIII-R criteria for schizophre-
nia were evaluated cross-sectionally along a naturalistic
perspective. Diagnoses were made by a senior psychiatrist
(P.S.) who personally interviewed the patients according
to the Structured Clinical Interview for DSM-III-R [14].
The subjects were excluded if had history of head injury,
alcohol abuse or serious neurological or physical disease.
None of the patients had been hospitalized in the past six
months and all were relapsing multiepisode patients able
to live in the community on maintenance AP therapy. The
mean age was 32.60 years (SD 7.48), and educational
level (number of successfully achieved classes) was 11.12
years (SD 2.85). Age at onset of symptoms was 23.00 ±
5.07 and length of illness 10.00 ± 6.65 years. All were tak-
ing APs, and the mean chlorpromazine-equivalent dose
[15,16] was 403 (SD 195.09) at the time of the evaluation.
In order to avoid variables that could reduce the power of
our investigation only patients on atypical or classical AP
mono-therapy, clinically stabilized and well functioning
in the community were selected. Patients were considered
clinically stabilized if no single item of the Positive and
Negative Syndrome Scale (PANSS) [17] exceeded the def-
inition 'mild' of the symptom (no more than 3 in a range
1–7). Good functionality was considered satisfied if the
subject reported 65 or more on the Global Assessment of
Functioning Scale (G.A.F., D.S.M. – IV) in the past 6
months.
All participants provided written informed consent after
complete description of the study, in accordance with the
local university institutional review board (Ethic Commit-
tee A.U.S.L. 4 L'Aquila)
Procedure
All subjects undertook two separate WCST sessions (128
cards). The first administration was along the standard
instructions as described by Heaton [18]; at the second
test administration, one hour after the first one, the sub-
jects were also required to 'verbally express' the matching
criterion before the card sorting. The performance was
considered poor or successful on the basis of the number
of categories achieved: poor if less o equal 3, successful if
4 or more according to previous studies [18,6,10]. Three
possible kinds of performance were considered: a) good
performance if the subject achieved 4 or more categories
both at the first and second administration; b) remediable
performance if the subject reported a poor performance at
the first but good at the second one; c) poor performance
at both the administrations.
WCST indexes used in the subsequent calculations are the
number of completed categories (CC), perseverative
errors (PE), total errors (TE) and unique errors (UR).BMC Psychiatry 2006, 6:3 http://www.biomedcentral.com/1471-244X/6/3
Page 3 of 6
(page number not for citation purposes)
Statistical analysis
Two-way ANOVA with remediation effect (standard
administration vs. verbalization) as within subjects factor
and atypical or classical AP therapy, as between subjects
factor, was performed separately on the WCST indexes as
dependent variables. Chi square and Student t-test were
used when necessary. All analyses yielding a p value of less
than 0.05 were considered significant.
Results
Forty of the 63 subjects (63.5%) were good performers
and 23 poor performers; of these latter 7 were the subjects
who remediated (the 30.4% of the poor performers at
standard WCST administration).
WCST performance and distribution of the total sample
along the 'remediation pattern' (Good, Remediable and
Poor) is reported in the Table 1. Both Good and Remedi-
ating subjects improved their performance while Poor
performers at both WCST administrations worsened in
terms of an increase of perseverative and total errors.
33 (52.4%) patients were taking atypical Aps. More males
than females were taking classical APs (83.3% of subjects
with classical AP treatment vs. 60.6% of subjects on atyp-
icals; Chi-Square = 3.97, d.f. = 1, P < 0.05). No differences
were seen in total PANSS score between the 2 groups (clas-
sical APs 72.6 ± 22.7, atypical 76.00 ± 18.90).
When further stratification was made on the basis of atyp-
ical or classical AP therapy, more poor performers not
remediating were seen in the sample with classical APs
(68.75% of the poor performers) while remediators were
only present in the subgroup with atypical APs (Chi-
Square = 9.28, d.f. = 2, P < 0.01 for 2 × 3 contingency
table). The WCST performances stratified by kind of
response to the standard and modified WCST administra-
tion and AP treatment are reported in the Table 2.
In the total sample, subjects with atypical APs showed less
perseverative and total errors than those on classical, both
at standard or modified administration; moreover sub-
jects assuming atypical APs only, significantly reduced
perseverative and total errors with verbalization.
When the kind of response to the modified administra-
tion was examined, an increase of perseverative and total
errors in poor performers was seen among the subjects on
classical APs only (interaction F = 5.50, P < 0.05). A simi-
lar interaction, without treatment or verbalization effect,
with an increase of unique errors in subjects on atypicals
was also seen.
Discussion
Subjects on atypical AP treatment reported a better execu-
tive function pattern in terms of WCST performance than
those on classical one. Moreover with the modified WCST
administration, remediation does occur in the atypical
group only, while poor performers on classical Aps did
worsen their performance.
Our observation is in agreement with the results from
Reeder et al. [19] study on executive skills reporting that
people on atypical AP medication show greater improve-
ment in working memory than those on classical; the
greatest benefit was gained by those who both received
Cognitive Remediation Therapy (CRT) and were pre-
scribed atypical antipsychotic medication. On the other
hand cognitive and psychosocial improvement from Cog-
nitive Enhancement Therapy (CET) was found unrelated
to the type of AP medication received [20]. This study was
not however focused on executive functions evaluation
Table 1: Distribution and WCST performance under standard or modified administration (verbalization) of the studied sample.
WCST Performance
WCST indexes Total sample (n = 63) Good (n = 40) Poor (n = 16) Remediable (n = 7)
Categories Achieved
Standard adm. 3.9 ± 2.4# 5.6 ± 0.9 0.6 ± 0.9* 2.0 ± 1.4§
Verbalization 4.6 ± 2.0 5.8 ± 0.4 1.3 ± 0.9 5.4 ± 0.7
Perseverative Errors
Standard adm. 17.4 ± 11.9* 14.4 ± 11.2# 23.8 ± 11.6** 20.0 ± 12.0
Verbalization 13.0 ± 17.6 4.8 ± 9.2 34.2 ± 19.0 11.0 ± 9.5
Total Errors
Standard adm. 30.9 ± 15.8§ 23.7 ± 13.8# 43.6 ± 10.8§ 42.8 ± 11.1*
Verbalization 23.6 ± 23.6 11.6 ± 15.6 53.4 ± 16.0 23.9 ± 15.1
Unique Errors
Standard adm. 1.9 ± 4.4* 1.1 ± 2.2* 1.8 ± 3.1 6.7 ± 10.6
Verbalization 0.8 ± 3.0 0.1 ± 0.4 1.6 ± 5.0 2.8 ± 4.5
Paired t-tests Standard adm vs Verbalization: * P < 0.05; ** P < 0.01; § P < 0.005; # P < 0.0005BMC Psychiatry 2006, 6:3 http://www.biomedcentral.com/1471-244X/6/3
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but neuropsychological composites and cognitive style
index are reported. Similarly in a randomized controlled
study of the effects of a cognitive remediation program on
adolescents with early onset schizophrenia, no significant
differences were found between the subjects on classical
and atypical Aps [21].
Moreover we replicated and expanded our previous obser-
vations [10,11] in a new larger independent sample,
although the percentage of subjects with good or remedi-
ating performance is remarkably different (good perform-
ers: present study 63.5%, previous study 26.9%;
remediating subjects: present study 30.4%, previous study
63.2%) [11]. This could be due to the selection bias,
because we studied subjects with good functionality only.
The naturalistic assignment of medication does not per-
mit to draw definitive conclusions about the effect of
medication on cognitive performance and its interaction
with cognitive remediation potential. Because of the
design of the study we do not state a priori explicit and
research criteria for AP treatment assignments. This deci-
sion has been left on clinical judgment. We cross-section-
ally studied and compared the two groups.
However medication type might be not strictly correlated
with clinical features of the disorder (i.e. development of
the illness, treatment failures, patient's cognitive profile
etc.): it could be possible that patients with more recent
onset have been treated with atypical APs because these
were more widely available, while older clinically stable
patients remained on classical APs. In other words, criteria
leading to the AP treatment choice could be influenced by
socioeconomical and historical factors too. These factors
are well beyond the scope of this article.
Another potential limitation could be due to fixed order
WCST administrations: the remediation could reflect
merely practice effect instead of an effect of verbalization.
However there is a dearth of literature on cognitive test
practice effects in schizophrenia, likely because of the
scarce possibility of improvement [22]. One study [23]
reported no evidence of practice effect, repeating executive
tests after 3 weeks, in stable treatment-resistant patients
Table 2: Distribution and WCST performance under standard or modified administration (verbalization) of subjects on atypical and 
classical AP treatment.
WCST indexes WCST performance















Categories Achieved a, e, i
Standard adm. 4.1 ± 2.4§ 3.8 ± 2.4* 5.8 ± 0.5 5.4 ± 1.2 0.0 ± 0.0 1.0 ± 1.0 2.0 ± 1.4§
Verbalization 5.0 ± 1.9 4.2 ± 2.1 5.9 ± 0.4 5.8 ± 0.5 0.8 ± 1.3 1.5 ± 0.6 5.4 ± 0.7
Perseverative Errors b, f, l
Standard adm. 13.8 ± 9.0 21.4 ± 13.5 10.5 ± 6.6# 18.7 ± 13.6§ 19.2 ± 7.8 26.0 ± 12.7§ 20.0 ± 12.0
Verbalization 6.9 ± 8.7 19.6 ± 22.2 2.7 ± 5.0 7.1 ± 12.1 18.8 ± 6.5 41.3 ± 18.7 11.0 ± 9.5
Total Errors c, g, m
Standard adm. 27.1 ± 13.9# 35.0 ± 17.0 19.1 ± 8.3# 28.8 ± 16.9** 38.8 ± 8.9 45.8 ± 11.2* 42.8 ± 11.1*
Verbalization 17.3 ± 17.6 30.5 ± 27.5 8.1 ± 9.7 15.4 ± 19.8 46.6 ± 10.0 56.6 ± 17.6 23.9 ± 15.1
Unique Errors d, h, n
Standard adm. 2.3 ± 5.6 1.5 ± 2.4§ 1.0 ± 2.4 1.2 ± 1.9* 1.6 ± 3.5 1.9 ± 3.1 6.7 ± 10.6
Verbalization 1.5 ± 4.1 0.1 ± 0.3 0.2 ± 0.6 0.0 ± 0.2 5.0 ± 8.6 0.1 ± 0.5 2.8 ± 4.5
2-way mixed ANOVAs
Total sample
AP treatment effect (A): a F = 1.0 NS; b F = 10.7 P < 0.0025; c F = 5.7 P < 0.025; d F = 1.8 NS.
Remediation effect (B): a F = 14.6 P < 0.0005; b F = 5.6 P < 0.025; c F = 10.3 P < 0.0025; d F = 5.6 P < 0.025.
A × B interaction: a F = 1.51 NS; b F = 2.04 NS; c F = 1.43 NS; d F = 0.47 NS
Good performers
AP treatment effect (A): e F = 1.5 NS; f F = 5.5 P < 0.025; g F = 4.8 P < 0.05; h F = 0.0 NS.
Remediation effect (B): e F = 2.9 NS; f F = 35.1 P < 0.0005; g F = 26.4 P < 0.0005; h F = 7.0 P < 0.025.
A × B interaction: e F = 1.1 NS; f F = 1.3 NS; g F = 0.2 NS; h F = 0.4 NS
Poor performers
AP treatment effect (A): i F = 4.9 p < 0.05; l F = 4.6 P < 0.05; m F = 1.7 NS; n F = 1.4 NS.
Remediation effect (B): i F = 6.4 P < 0.025; l F = 4.9 P < 0.05; m F = 7.6 P < 0.025; n F = 0.6 NS.
A × B interaction: i F = 0.2 NS; l F = 5.5 P < 0.05; m F = 0.2 NS; n F = 6.0 P < 0.05
Paired t-tests Standard adm vs Verbalization: * P < 0.05; ** p < 0.01; § P < 0.005; # P < 0.0005BMC Psychiatry 2006, 6:3 http://www.biomedcentral.com/1471-244X/6/3
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treated with clozapine. Stratta et al. [10] administering
four times WCST in two days did not observe improve-
ment in patients on classical AP medication. Harvey et al.
[24] found that the degree of improvement with practice
was greater in patients administered an atypical medica-
tion than in those given typical medication. However the
possibility to achieve practice effect, previously limited by
classical AP treatment, could also been an important
result. The restoration of a practice effect is real advantage
although does not represent actual procognitive effective-
ness [25,26]. Follow up- studies are needed to better clar-
ify the meaning of the 'remediation'.
Conclusion
Although we are still far from the point of a meaningful
integration of cognitive findings with AP treatment out-
come, results from neuropsychological assessment could
provide guidance to the patient's management. We could
hypothesize that patients who do not remediate, even if in
a state of clinical response to classical AP treatment, could
have a trial with atypicals to evaluate a chance of cognitive
improvement. On the other hand subjects who do not
show improvement could benefit from a different atten-
tional training using rehabilitation methodologies more
weighted on procedural learning or practice effect [27].
Improvement in cognitive functioning is one of the most
important clinical targets in the treatment of schizophre-
nia [28]. In the cognitive 'puzzle', we propose that the
remediation 'piece' is associated with better cognitive
functioning and atypical AP treatment. We need further
study to evaluate how these three variables are connected
and what kind of clinical predictions they offer.
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